What is the recommended apixaban dosing regimen for venous thromboembolism prophylaxis after an elective total hip replacement in an adult with normal renal function (creatinine clearance ≥30 mL/min) and no severe hepatic disease?

Apixaban Dosing for DVT Prophylaxis After Hip Replacement

For VTE prophylaxis after total hip replacement in adults with normal renal function, apixaban should be dosed at 2.5 mg orally twice daily, initiated 12 to 24 hours after surgery, and continued for 35 days. 1

Dosing Regimen

• Dose: 2.5 mg orally twice daily 1
• Initiation timing: 12 to 24 hours after surgical wound closure 1, 2
• Duration: 35 days (5 weeks) after hip replacement surgery 3, 1

This represents the FDA-approved prophylactic dosing regimen, which differs substantially from therapeutic dosing used for VTE treatment (10 mg twice daily for 7 days, then 5 mg twice daily) 1

Evidence Supporting This Regimen

The ADVANCE-3 trial demonstrated superior efficacy of apixaban 2.5 mg twice daily compared to enoxaparin 40 mg daily for hip replacement prophylaxis, with a 64% relative risk reduction in VTE (1.4% vs 3.9%; RR 0.36; 95% CI 0.22-0.54; P<0.001). 4, 2

• Major and clinically relevant nonmajor bleeding rates were similar between apixaban (4.8%) and enoxaparin (5.0%), demonstrating comparable safety 2
• Apixaban is recommended as a first-line choice by the American College of Chest Physicians for VTE prophylaxis after hip replacement 4

Renal Function Considerations

For patients with normal renal function (CrCl ≥30 mL/min):

• No dose adjustment is required for the prophylactic 2.5 mg twice daily regimen 1
• Apixaban has multiple elimination pathways with only 27% renal clearance, making it suitable for patients with mild-to-moderate renal impairment 4
• Use with caution if CrCl 15-30 mL/min; avoid if CrCl <15 mL/min 4

Critical Timing and Safety Considerations

Initiation timing is crucial: The first dose should be given 12-24 hours post-surgery, which differs from enoxaparin that is typically started preoperatively 1, 2. This delayed initiation balances thromboprophylaxis with surgical hemostasis.

Drug interactions to avoid:

• Potent CYP3A4 inhibitors are contraindicated as they increase apixaban plasma concentrations 5
• P-glycoprotein inhibitors may also increase drug levels and require consideration 3

Perioperative Management

If apixaban needs to be discontinued for subsequent procedures:

• Discontinue at least 48 hours prior to elective surgery with moderate-to-high bleeding risk 4, 1
• Discontinue at least 24 hours prior for low bleeding risk procedures 1
• Bridging anticoagulation during the 24-48 hour interruption is not generally required 1

Common Pitfalls to Avoid

Do not confuse prophylactic and therapeutic dosing: The 2.5 mg twice daily prophylactic dose is substantially lower than the 10 mg twice daily therapeutic dose used for acute VTE treatment 1. Using therapeutic dosing for prophylaxis unnecessarily increases bleeding risk.

Do not perform neuraxial anesthesia with inadequate apixaban discontinuation time: Spinal or epidural anesthesia requires sufficient drug clearance to minimize bleeding risk, particularly in elderly patients or those with renal impairment 3

Avoid overlapping anticoagulants: When transitioning from perioperative heparin prophylaxis to apixaban, ensure the first therapeutic dose of apixaban is given 12 hours after the last prophylactic LMWH dose to prevent excessive anticoagulation 3